Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Share-based Compensation (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Share-based Compensation data on record, last reported at $11.6 million in Q4 2022.

  • For Q4 2022, Share-based Compensation rose 2.59% year-over-year to $11.6 million; the TTM value through Dec 2022 reached $46.7 million, up 17.91%, while the annual FY2025 figure was $20.7 million, 59.97% down from the prior year.
  • Share-based Compensation reached $11.6 million in Q4 2022 per AVIR's latest filing, up from $11.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $11.9 million in Q2 2022 and bottomed at $189000.0 in Q1 2020.
  • Average Share-based Compensation over 3 years is $7.8 million, with a median of $10.5 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: skyrocketed 4688.04% in 2021, then rose 2.59% in 2022.
  • A 3-year view of Share-based Compensation shows it stood at $2.8 million in 2020, then surged by 302.38% to $11.4 million in 2021, then rose by 2.59% to $11.6 million in 2022.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $11.6 million in Q4 2022, $11.5 million in Q3 2022, and $11.9 million in Q2 2022.